|
Market Closed -
Nasdaq
00:00:00 21/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 1.980 USD | +5.32% |
|
-0.50% | -42.77% |
| 08-25 | Grace Therapeutics Files for Resale of Up to 4.8 Million Shares | MT |
| 08-14 | Grace Therapeutics, Inc. Reports Impairment charges for the First Quarter Ended June 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GRACE THERAPEUTICS, INC. | Bio Therapeutic Drugs | +5.32% | -0.50% | -42.77% | -38.51% | -81.67% | 41.65M |  | | |
- Stock Market
- Stocks
- GRCE Stock
- Charts Grace Therapeutics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
